Abeona Therapeutics Inc (ABEO)
4.465
+0.06
(+1.48%)
USD |
NASDAQ |
May 20, 16:00
4.465
0.00 (0.00%)
After-Hours: 17:27
Abeona Therapeutics Cash from Financing (Quarterly): 25.44M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 25.44M |
| December 31, 2023 | 7.467M |
| September 30, 2023 | 22.98M |
| June 30, 2023 | 6.618M |
| March 31, 2023 | -0.004M |
| December 31, 2022 | 42.77M |
| September 30, 2022 | 4.189M |
| June 30, 2022 | -3.782M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 16.33M |
| September 30, 2021 | 0.173M |
| June 30, 2021 | 2.479M |
| March 31, 2021 | 5.878M |
| December 31, 2020 | 0.003M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 1.933M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 96.53M |
| September 30, 2019 | 4.34M |
| June 30, 2019 | 13.01M |
| March 31, 2019 | 0.028M |
| December 31, 2018 | -0.001M |
| September 30, 2018 | 3.079M |
| June 30, 2018 | 0.57M |
| March 31, 2018 | 1.829M |
| Date | Value |
|---|---|
| December 31, 2017 | 87.26M |
| September 30, 2017 | 5.06M |
| June 30, 2017 | 0.084M |
| March 31, 2017 | 0.001M |
| December 31, 2016 | 41.37M |
| September 30, 2016 | 1.019M |
| June 30, 2016 | 0.15M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 15.41M |
| June 30, 2015 | 20.64M |
| March 31, 2015 | -0.40M |
| December 31, 2014 | 12.46M |
| September 30, 2014 | 0.25M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.018M |
| June 30, 2013 | 0.011M |
| March 31, 2013 | |
| December 31, 2012 | 1.904M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | |
| December 31, 2011 | 3.076M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.782M
Minimum
Jun 2022
96.53M
Maximum
Dec 2019
12.32M
Average
4.264M
Median
Cash from Financing (Quarterly) Benchmarks
| T2 Biosystems Inc | 2.202M |
| INVO Bioscience Inc | -0.1415M |
| Perspective Therapeutics Inc | 166.33M |
| Electromed Inc | 0.056M |
| Xtant Medical Holdings Inc | 5.179M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.54M |
| Cash from Investing (Quarterly) | -7.817M |
| Free Cash Flow | -40.64M |
| Free Cash Flow Per Share (Quarterly) | -0.5588 |
| Free Cash Flow Yield | -37.99% |